Healthcare: approx. 70%
Medical Technology: approx. 20%
Research and Development: approx. 10%

TOP 3 Markets:

1. China: approx. 50%
2. USA: approx. 30%
3. Europe: approx. 15%

Micro-Tech (Nanjing) Co., Ltd is strongly anchored in the healthcare sector, with the majority of revenues coming from the manufacturing and distribution of medical devices. The company's main markets are China, the USA, and Europe, with China accounting for the largest share of revenue.

The company benefits from the growing demand for innovative medical technology solutions, especially in developed markets. The strategic focus on research and development also supports the introduction of new products and strengthens the market position in these regions.

Production Sites: Nanjing, China

Micro-Tech (Nanjing) Co., Ltd mainly produces its products in Nanjing, China. The company is known for its medical devices and endoscopy products and strategically located its production facilities in the region to benefit from the well-developed infrastructure and available resources.

Choosing Nanjing as a production site enables the company to optimize production costs and take advantage of proximity to key suppliers and markets in Asia.

Revenue Growth: 18% (2025) R&D Investments: 12% of revenue (2025)

Micro-Tech (Nanjing) Co., Ltd is pursuing a growth strategy that heavily focuses on innovation and international expansion. The company is investing significantly in research and development to expand and enhance its range of medical devices. This includes particularly the development of new technologies and the improvement of existing products to meet the increasing demands in the healthcare sector.

Another key focus of the growth strategy is the exploration of new markets outside of China. Micro-Tech plans to strengthen its presence in Europe and North America to benefit from the demand for high-quality medical devices in those regions. Partnerships and strategic alliances with local companies are part of this expansion strategy.

Additionally, the company is focusing on digitizing its processes and products to achieve efficiency gains and explore new business opportunities. This includes both the implementation of modern manufacturing technologies and the use of digital platforms to enhance customer service.

Raw Materials/Materials: Stainless steel, silicone, plastics

Main Import Countries: Japan, Germany, USA

Micro-Tech (Nanjing) Co., Ltd is a leading company in the manufacturing of medical devices, especially endoscopes. For the production of these devices, the company imports various raw materials and materials. Stainless steel is often imported from Japan, as the country is known for its high-quality steel products. The company often sources silicone and plastics, needed for the production of endoscope components, from Germany and the USA, known for their advanced technologies and materials in medical technology.

This import strategy enables Micro-Tech to produce high-quality products that meet international standards. By using materials from leading industrial countries, the company secures a competitive advantage in the global market.

Market Share in China: Estimated at 25% (2026)
R&D Expenses: 12% of revenue (2025)
International Expansion: 15 new markets (2024-2026)

Micro-Tech (Nanjing) Co., Ltd has established itself in recent years as a leading provider in the medical technology industry, especially in the field of endoscopy. The estimated market share of 25% in China demonstrates the company's strong position in the domestic market. This dominance is supported by continuous investments in research and development, amounting to 12% of revenue, which is above the industry average.

Furthermore, the company has significantly expanded its international presence by entering 15 new markets between 2024 and 2026. This expansion has not only increased revenue but also enhanced global brand awareness. Micro-Tech's competitive advantage lies in the combination of technological innovation, a strong market presence in China, and a successful international expansion strategy.

Institutional Investor Share: 45% (estimated for 2026)
Insider Buys/Sells: No significant transactions in the last year (estimated for 2026)

The institutional investor share in Micro-Tech (Nanjing) Co., Ltd is estimated to be around 45%. This suggests that a significant number of shares are held by institutional investors, indicating a certain level of confidence in the company's long-term performance.

Regarding insider buys or sells, there have been no significant transactions in the last year. This could indicate that the management and other insiders currently do not expect significant changes in the company's valuation or that they are satisfied with the current corporate strategy.

Market share of Micro-Tech (Nanjing) Co., Ltd: 12% (2026, estimated)

Major competitors and their market shares:

1. Boston Scientific Corporation: 20%
2. Olympus Corporation: 18%
3. Medtronic plc: 15%
4. Cook Medical: 14%
5. Micro-Tech (Nanjing) Co., Ltd: 12%
6. Fujifilm Holdings Corporation: 10%
7. Pentax Medical (HOYA Corporation): 8%
8. Conmed Corporation: 3%

In recent years, Micro-Tech (Nanjing) Co., Ltd has established a solid market share of around 12%, attributed to its innovation capabilities and strong presence in the Asian market. The company's moat mainly lies in its specialization in endoscopic technologies and its ability to offer cost-effective solutions.

In comparison to larger competitors like Boston Scientific and Olympus, which have extensive product portfolios and strong global distribution networks, Micro-Tech's moat is less pronounced. These companies have a significant advantage due to their long-standing market presence and continuous investments in research and development.

However, Micro-Tech could further enhance its moat through targeted expansions and strategic partnerships. A focus on innovative product developments and exploring new markets could also help strengthen its competitive position.

Revenue Growth: 18% (2025) R&D Expenses: 12% of revenue (2025) Market Share in the Endoscopy Industry: 10% (2025)

Micro-Tech (Nanjing) Co., Ltd recorded a revenue growth of 18% in 2025, attributed to strong demand for their medical products, particularly in the endoscopy industry. The company continues to invest heavily in research and development, with expenses accounting for 12% of revenue. This indicates a strategic focus on developing innovative products and strengthening their market position.

With a 10% market share in the endoscopy industry, Micro-Tech demonstrates a solid presence and has potential for further growth, especially in emerging markets. Ongoing investments in R&D could lead to technological breakthroughs that propel the company forward.

Overall, Micro-Tech could be an attractive investment considering the potential for long-term growth and innovation. However, investors should also consider the competitive landscape and regulatory developments in the healthcare sector.

Dividend payment: Yes, Micro-Tech (Nanjing) Co., Ltd pays a dividend.
Dividend yield: 1.8% (2026, estimated)
Payout ratio: 35% (2025, estimated)

Micro-Tech (Nanjing) Co., Ltd has started to pay dividends regularly in recent years. The current dividend yield is approximately 1.8%, which can be considered moderate compared to other companies in the industry.

The payout ratio of about 35% indicates that the company is returning a portion of its profits to shareholders while retaining enough funds for reinvestment and growth. This suggests a certain reliability in dividend payment, as the company does not distribute all of its profits, thus providing a buffer for economic fluctuations.